A New Psoriatic Arthritis Approval Puts Care Continuity in Focus

Valore's take

The FDA’s approval of tildrakizumab for adults with psoriatic arthritis brings the work surrounding a new treatment option into focus. Our view is that an approval is one milestone, while continuous care requires attention to what happens between appointments. For pharmacist-enabled care, that means defining how medication-related questions, access concerns and follow-up responsibilities move across the care team.

We see pharmacists as part of that ongoing structure, rather than a separate stop in the process. Their role should be connected to the broader team, with clear communication channels and a shared understanding of who is responsible for each next step. A new approval is a useful occasion to examine those arrangements without assuming that every organization has the same workflows or resources.

At Valore, we approach this headline through that operational lens. The approval alone does not describe how ongoing care will be organized. Our focus is on the infrastructure around medication use: documented handoffs, defined responsibilities and a place for pharmacists in continuing communication. Those are central considerations in how we think about continuous care.